Abstract
Despite progress, chemotherapy yields disappointing results in metastatic pancreatic ductal adenocarcinoma and median overall survival is less than 12 months. Mark H O’Hara and colleagues1 investigated how to improve this figure by building on a nab-paclitaxel plus gemcitabine chemotherapy backbone in a phase 1b trial assessing the recommended phase 2 dose of the CD40 agonistic monoclonal antibody APX005M, with and without nivolumab, in an attempt to sensitise an immunologically cold disease. The authors provide an example of a smart strategic project of drug development and multicentre cooperation aimed at boosting and fostering the acquisition of sound and reliable data by rapid execution of a well designed and well managed trial.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
